Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
Hannover Medical School
mi
from
Hannover,
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
Hannover Medical School
mi
from
Hannover,
Click here to add this to my saved trials
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
TX2® Low Profile TAA Endovascular Graft
Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
The University of California Irvine
mi
from
Orange, CA
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Yale School of Medicine Digestive Diseases
mi
from
New Haven, CT
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Yale School of Medicine Digestive Diseases
mi
from
New Haven, CT
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mt Sinai Hospital
mi
from
New York, NY
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mt Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Rochester General Hospital
mi
from
Rochester, NY
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Stony Brook University
mi
from
Stony Brook, NY
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Stony Brook University
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mcguire Va Medical Center
mi
from
Richmond, VA
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mcguire Va Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)
Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)
Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Genomics of Primary Sclerosing Cholangitis (PSC)
P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Genomics of Primary Sclerosing Cholangitis (PSC)
P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated:  12/31/1969
Navy Medical Research Center
mi
from
Silver Springs, MD
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated: 12/31/1969
Navy Medical Research Center
mi
from
Silver Springs, MD
Click here to add this to my saved trials
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated:  12/31/1969
Saint Louis University
mi
from
Saint Louis, MO
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated: 12/31/1969
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Bivalent Norovirus Vaccine Study
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gene Expression in Inflammatory Bowel Disease
Gene Expression in Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Gene Expression in Inflammatory Bowel Disease
Gene Expression in Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
Compassionate Use of a Fish Oil-derived Intravenous Fat Emulsion (Omegaven) to Reverse Parenteral Nutrition (PN) Induced Cholestasis
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
Compassionate Use of a Fish Oil-derived Intravenous Fat Emulsion (Omegaven) to Reverse Parenteral Nutrition (PN) Induced Cholestasis
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effect of High Omega-3 Fish Intake on Lipid Peroxidation
Effect of High Omega-3 Fish Intake on Lipid Peroxidation
Status: Enrolling
Updated:  12/31/1969
USDA ARS Grand Forks Human Nutrition Research Center
mi
from
Grand Forks, ND
Effect of High Omega-3 Fish Intake on Lipid Peroxidation
Effect of High Omega-3 Fish Intake on Lipid Peroxidation
Status: Enrolling
Updated: 12/31/1969
USDA ARS Grand Forks Human Nutrition Research Center
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
Use of Omegaven for Parenteral Nutrition Associated Liver Disease
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
Use of Omegaven for Parenteral Nutrition Associated Liver Disease
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial
Veritas Laparoscopic PEH Repair Pilot Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial
Veritas Laparoscopic PEH Repair Pilot Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Hospital,
mi
from
Mobile, AL
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mercy San Juan Medical Center
mi
from
Carmichael, CA
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials